The Management Team.

Dr. Robert T. Dorr – President & Chief Executive Officer
Dr. Evan Hersh – Executive VP & Chief Medical Officer
Chris Richied – VP & Chief Financial Officer
Dr. William A. Remers – VP, Chemistry and Manufacturing
Steve Steinman –
VP, Regulatory and Quality Assurance.
Kathryn Grenier – VP, Clinical Operations

Robert T. Dorr, Ph.D., R.Ph, is Chief Executive Officer. He is a Professor of Pharmacology and Toxicology and is Director of the Pharmacology Program at the Arizona Cancer Center. He also directs the Research Pharmacy of the Arizona Cancer Center. Dr. Dorr has expertise in the preclinical toxicology of anticancer and cancer preventative drugs. He has directed the Clinical Pharmacology components of many cancer drug trials and is the author of one of the leading books on anticancer drugs. Dr. Dorr has served on many pharmaceutical company advisory boards and has been founder or cofounder of three pharmaceutical or related companies, including Clinuvel Ltd and Paladin Corporation as well as AmpliMed.

Evan M. Hersh, M.D. Dr. Hersh serves as the Company's Executive Vice President and Chief Medical Officer. He is a Professor of Medicine, Assistant Director for Experimental Therapeutics and Translational research at the Arizona Cancer Center. He was formerly Chief of Hematology and Oncology at the Arizona Cancer Center and before that he was Chairman of the Department of Clinical Immunology (which he founded) at the MD Anderson Cancer Center. Dr. Hersh is a medical oncologist and clinical immunologist with expertise in preclinical and clinical evaluations of immunologic and anticancer agents. He discovered the activity of Amplimexon™ against multiple myeloma. He serves on the Scientific and Medical Advisory Boards of six companies at present. He has also served as a member of the Oncologic Drug Advisory Board of the FDA.

Christopher R. Richied is Chief Financial Officer.  He has worked in IPO investment banking and biotech venture capital, and was CEO of EnzyMed, a successful biotech company acquired by Albany Molecular.  Most recently he worked in the finance department of the Burnham Institute for Medical Research in La Jolla, CA.  Chris has his MBA from Harvard Business School, an M.S. in Management Information Systems from the University of Arizona, and a B.S. in Chemical Engineering from Ohio State University. 

William A. Remers, Ph.D., is Vice President for Chemistry and Manufacturing. He is a Professor of Medicinal Chemistry Emeritus in the College of Pharmacy. Previously, he held important synthetic chemistry positions with major pharmaceutical companies. Dr. Remers is an expert in the synthesis and structure activity relationships of anticancer drugs. He helped to conceive AmpliMed's Azonafide series and he has synthesized the 30 Amplimexon analogues and the 150 azonafides. Dr. Remers has over 20 years of experience in both academic and industrial drug synthesis.

Steve Steinman, Vice President of Regulatory Affairs and Quality Assurance and also supervises QA/QC for the Company. Mr. Steinman founded and served as President of Steinman Associates, a prominent Washington, D.C. based consulting company that provided comprehensive pharmaceutical operations and services including regulatory affairs, drug manufacturing, quality assurance and clinical trials management. Mr. Steinman has 30 years of experience in the pharmaceutical industry.

Kathryn Grenier, MT, MPA/HSA, is Vice President of Clinical Operations. Ms. Grenier has over 18 years of experience in operations management of clinical programs for pharmaceutical, medical device and diagnostic companies. Prior to joining the Company, Ms. Grenier was the Associate Director of Clinical Trials at the University of Arizona, Arizona Cancer Center. Ms. Grenier served as Vice President of Clinical Affairs, Somnus Medical Technologies/Gyrus Group PLC; Director of Clinical Research at Clinical Pathways, a CRO company; and clinical management and technical positions with Becton Dickinson Immunocytometry Systems. Ms. Grenier received her Master’s Degree in Public Administration/Health Services Administration from the University of San Francisco, a B.S. in Medical Technology and a certificate in Business Management, both from the University of Utah.

Notice: AmpliMed® and Amplimexon® are registered trademarks of AmpliMed Corporation; Amplizone™ and Inspired Thinking - Advancing Cancer Research™ are trademarks of AmpliMed Corporation

All content copyright © 2006 AmpliMed Corporation